European Academy of Neurology (EAN) Congress 2026 | iPharmaCenter

Nipocalimab Shows Durable MG‑ADL Gains Across Subgroups In Vivacity‑MG3

Johnson & Johnson highlighted how nipocalimab performs across different points in the gMG journey rather than only in a single, homogeneous trial population. The new work looked at adults with antibody‑positive generalized myasthenia gravis, including those early after diagnosis, individuals with lower symptom burden at baseline, and patients who experienced common infections during follow up.

IMAAVY is a neonatal Fc receptor blocker that is designed to reduce circulating IgG autoantibodies, which play a central role in driving weakness and fatigability in many people living with gMG. By interrogating MG‑ADL outcomes in these different subgroups, the analyses aim to clarify how early and broadly in the disease course FcRn inhibition might be clinically useful.

 

Also read: CVS Pharmacy Joins Medicare GLP-1 Bridge and Scales Weight‑Loss Access Across the U.S

Early‑course disease: MG‑ADL improvements within five years of diagnosis

One analysis from Vivacity‑MG3 focused on patients whose generalized myasthenia gravis had been diagnosed within about five years, a timeframe where advanced therapies may be used less routinely. In this subgroup, adding nipocalimab to standard of care produced a larger improvement in MG‑ADL scores at Week 24 than placebo plus standard care.

Mean MG‑ADL change at Week 24 was approximately a 4.9‑point reduction in the IMAAVY arm compared with a 2.7‑point reduction in the placebo arm, reflecting a deeper impact on daily activities and self‑reported function early in the disease course. Investigators also applied a strict definition of sustained meaningful clinical improvement based on MG‑ADL that required benefits to persist for at least 20 weeks. A greater proportion of patients receiving nipocalimab reached this sustained improvement threshold versus placebo, suggesting that targeting IgG early can support prolonged symptom control rather than only short‑lived gains.

Also read: Top 10 Pharma Companies by Revenue in 2025

Lower baseline symptom burden: MG‑ADL outcomes in milder gMG

A second analysis examined adults who entered Vivacity‑MG3 with lower baseline symptom burden, a group where the decision to escalate beyond conventional therapies can be more nuanced. Here, IMAAVY plus standard of care again delivered a more pronounced improvement in MG‑ADL scores at Week 24 than placebo plus standard care.

In this lower‑burden cohort, mean MG‑ADL reductions were about 4.5 points with nipocalimab compared with 2.3 points with placebo, indicating that even patients starting from milder disease can experience additional clinically relevant gains in daily functioning. As in the early‑course group, a higher proportion of people on nipocalimab achieved sustained meaningful clinical improvement in MG‑ADL, providing extra context for clinicians considering FcRn inhibition in less severely affected patients.

Disease control around common infections: MG‑ADL stability

Because infections are a well‑recognized trigger for symptom flares and hospitalisations in myasthenia gravis, Johnson & Johnson also looked at MG‑ADL and other measures around episodes of common infection in Vivacity‑MG3. In the nipocalimab arm, symptom improvements that had been achieved prior to infection were largely maintained over the roughly two‑week period following the infectious event.

Median MG‑ADL change in the IMAAVY group during this post‑infection window remained close to zero, indicating stability rather than deterioration, whereas patients on placebo showed modest worsening. These data suggest that, for individuals receiving FcRn blockade, disease control in terms of daily activity scores can persist through periods when exacerbations are typically more likely, although infections themselves remain common and still warrant careful management.